



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Detection of potential enteric pathogens in children with severe acute gastroenteritis using the filmarray:
Results from a three - years hospital-based survey in Northern Italy

This is a pre print version of the following article:

Original

Detection of potential enteric pathogens in children with severe acute gastroenteritis using the filmarray:
Results from a three - years hospital-based survey in Northern Italy / De Conto, F.; Di Stefano, S.; Buttrini,
M.; Maccari, C.; Arcangeletti, M. C.; Chezzi, C.; Calderaro, A.. - In: DIAGNOSTIC MICROBIOLOGY AND
INFECTIOUS DISEASE. - ISSN 0732-8893. - 102:3(2022), p. 115611.115611.
[10.1016/j.diagmicrobio.2021.115611]

Availability:

This version is available at: 11381/2919550 since: 2022-03-23T16:54:44Z

Publisher:

Elsevier Inc.

Published

DOI:10.1016/j.diagmicrobio.2021.115611

Terms of use:

openAccess

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

(Article begins on next page)

Diagnostic Microbiology & Infectious Disease

DETECTION OF POTENTIAL ENTERIC PATHOGENS IN CHILDREN WITH SEVERE ACUTE GASTROENTERITIS USING THE FILMARRAY: RESULTS FROM A THREE-YEARS HOSPITAL-BASED SURVEY IN NORTHERN ITALY

--Manuscript Draft--

| | |
|------------------------------|---|
| Manuscript Number: | |
| Article Type: | Original article |
| Keywords: | Acute gastroenteritis, childcare setting, multiplex PCR, filmarray, infectious disease control, rapid diagnostic assay. |
| Corresponding Author: | Flora De Conto University of Parma: Universita degli Studi di Parma Parma, ITALY |
| First Author: | Flora De Conto |
| Order of Authors: | Flora De Conto SHARON DI STEFANO MIRKO BUTTRINI CLARA MACCARI MARIA CRISTINA ARCANGELETTI CARLO CHEZZI ADRIANA CALDERARO |
| Abstract: | <p>Acute gastroenteritis (AGE) are leading causes of morbidity and mortality in children. To control AGE, rapid identification of enteric pathogens is needed. The AGE aetiology was investigated from 2018 to 2020 in 2,066 children in Parma (Italy), using the filmarray. Pathogens were detected in 1,101 (53.3%) stool samples; 796 (72.3%) were single infections and 305 (27.7%) mixed infections (72.3% vs. 27.7%, $P < 0.0001$). The highest infection incidence (68.2%) was assessed in children aged 0-5 years.</p> <p>Enteropathogenic Escherichia coli (EPEC) was the most frequently identified pathogen (21.14%), followed by Clostridioides difficile (11.5%), Norovirus (11.44%), and Campylobacter (10.17%). EPEC, Campylobacter, enteroaggregative Escherichia coli, Norovirus, and Rotavirus showed seasonality. The pathogen detection rate decreased between 2018 and 2020 (41.1% vs. 22%, $P < 0.0001$), because of the preventive measures imposed by the severe acute respiratory syndrome coronavirus 2 pandemic. A putative aetiology in half the children examined and an estimate of enteric pathogens epidemiology were assessed.</p> |
| Suggested Reviewers: | VITO MARTELLA Universita degli Studi di Bari Dipartimento di Medicina Veterinaria vito.martella@uniba.it |
| | ELEONORA PONTERIO Istituto Superiore di Sanità: Istituto Superiore Di Sanita eleonoraponterio@yahoo.it |
| | SARAH N. BUSS University of Nebraska Medical Center sarah.buss@wyo.gov |
| | MELISSA O'NEAL University of South Carolina College of Pharmacy mponeal@email.sc.edu |
| | JEREMY MEYER Geneva University Hospitals: Hopitaux Universitaires Geneve jeremy.meyer@hcuge.ch |

Highlights

- FAGP assessed the putative aetiology in Italian children with AGE from 2018 to 2020
- Bacteria were the most common enteric pathogens and single infections predominated
- The detection rate of enteric pathogens was highest in young children (0-5 years)
- Infection incidence showed seasonal variations for some enteric pathogens
- Preventive measures against SARS-CoV-2 pandemic decreased pathogens detection

1 **DETECTION OF POTENTIAL ENTERIC PATHOGENS IN CHILDREN WITH SEVERE**
2 **ACUTE GASTROENTERITIS USING THE FILMARRAY: RESULTS FROM A THREE-**
3 **YEARS HOSPITAL-BASED SURVEY IN NORTHERN ITALY**

4 Flora De Conto*, Sharon Di Stefano, Mirko Buttrini, Clara Maccari, Maria Cristina Arcangeletti,
5 Carlo Chezzi, Adriana Calderaro

6 Department of Medicine and Surgery, University of Parma, Viale Antonio Gramsci 14, 43126

7 Parma, Italy

8

9

10

11 * Author for correspondence:

12 E-mail: flora.deconto@unipr.it fax: +39 0521 993620

13

14 Running title: AGE diagnosis in children in Italy

15

16

17

18

19

20

21

22

23 **Conflict of Interest**

24 Adriana Calderaro declares that she is an Editorial Member of *Diagnostic Microbiology and*
25 *Infectious Disease*.

26

27 **ABSTRACT**

28 Acute gastroenteritis (AGE) are leading causes of morbidity and mortality in children. To control
29 AGE, rapid identification of enteric pathogens is needed.

30 The AGE aetiology was investigated from 2018 to 2020 in 2,066 children in Parma (Italy), using
31 the filmarray. Pathogens were detected in 1,101 (53.3%) stool samples; 796 (72.3%) were single
32 infections and 305 (27.7%) mixed infections (72.3% vs. 27.7%, $P<0.0001$). The highest infection
33 incidence (68.2%) was assessed in children aged 0-5 years.

34 Enteropathogenic *Escherichia coli* (EPEC) was the most frequently identified pathogen (21.14%),
35 followed by *Clostridioides difficile* (11.5%), Norovirus (11.44%), and *Campylobacter* (10.17%).
36 EPEC, *Campylobacter*, enteroaggregative *Escherichia coli*, Norovirus, and Rotavirus showed
37 seasonality. The pathogen detection rate decreased between 2018 and 2020 (41.1% vs. 22%,
38 $P<0.0001$), because of the preventive measures imposed by the severe acute respiratory syndrome
39 coronavirus 2 pandemic. A putative aetiology in half the children examined and an estimate of
40 enteric pathogens epidemiology were assessed.

41

42 **ABBREVIATIONS**

43 AdV: adenovirus

44 AGE: acute gastroenteritis

45 EAEC: enteroaggregative *Escherichia coli*

46 EIEC: *Shigella*/enteroinvasive *Escherichia coli*

47 EPEC: enteropathogenic *Escherichia coli*

48 ETEC: enterotoxigenic *Escherichia coli*

49 FAGP: FilmArray Gastrointestinal panel

50 GDH: glutamate dehydrogenase enzyme

51 IC: immunochromatographic assay

52 LAMP: Loop-mediated isothermal amplification

53 NoV: norovirus

54 PCR: polymerase-chain reaction

55 RV: rotavirus

56 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

57 SaV: sapovirus

58 STEC: *Shiga*-like toxin-producing *Escherichia coli*

59

60

61 **KEYWORDS**

62 Acute gastroenteritis, childcare setting, multiplex PCR, filmarray, infectious disease control, rapid

63 diagnostic assay.

64

65 **1. INTRODUCTION**

66 Acute gastroenteritis (AGE) are a leading cause of childhood morbidity and mortality with relevant
67 costs for societies. AGE with diarrhea and/or vomiting can last several days and be associated with
68 symptoms such as abdominal pain, cramping, fever, malaise, and anorexia. There are nearly 1.7
69 billion cases of childhood diarrheal disease worldwide every year, killing about 525,000 children
70 [1].

71 The etiologic agents of childhood diarrheal disease include bacteria, parasites, and viruses [2]. Age,
72 social, and geographic factors modulate the incidence of enteric pathogens [3].

73 Most cases of childhood diarrheal disease are due to viral infections principally caused by Rotavirus
74 and Norovirus [4,5]. Despite the vaccine, Rotavirus still causes hospitalization [6]. Bacteria may
75 cause severe diarrhea (bloody stools), and high fever, needing hospital management. Moreover,
76 some enteric bacteria may spread systematically [7]. With enhanced globalization and immigration,
77 clinicians of developed countries diagnose several cases of diarrhea due to protozoa not habitually
78 circulating [7].

79 Although the epidemiological/clinical evaluation of AGE not always allows differentiating among
80 bacterial, viral, and parasitological etiology, it guides the laboratory diagnosis. Prompt diagnosis
81 optimizes the patient treatment, avoiding incorrect antibiotic use and reducing hospitalization.

82 Conventional methods are laborious, time-consuming, and costly. Multiplex molecular assays
83 considerably reduce the time to result, detecting a greater number of pathogens [8].

84 This large-scale hospital-based survey in Parma (Northern Italy) from 2018 to 2020 aims to assess
85 the epidemiology of AGE pathogens in children with a multiplex polymerase chain reaction (PCR)-
86 based platform. Moreover, the impact of the severe acute respiratory syndrome coronavirus 2
87 (SARS-CoV-2) pandemic on AGE dynamics was investigated.

88 **2. MATERIALS AND METHODS**

89 *2.1 Study setting*

90 This study was performed at the Microbiology and Virology Units of the University-Hospital of
91 Parma, a 1,044-bed tertiary care center with more than 50,000 admissions per year.

92 The inclusion criteria were subjects ≤ 14 years old and occurrence of AGE symptoms (diarrhea,
93 vomiting, abdominal pain, and fever).

94 From January 2, 2018 to December 31, 2020, 2,066 stool samples from as many children were
95 submitted to the laboratory for diagnostic purposes. Table 1 shows the demographic characteristics
96 of the examined children, whose age ranged from ≥ 13 days to 14 years and 3 months.

97 Laboratory diagnosis was performed upon medical order. The results were reported in the clinical
98 records of the patients as answer to a clinical suspicion. Patients' identity and medical information
99 were protected and remained anonymous.

100

101 *2.2 Molecular assays*

102 For the FilmArray gastrointestinal panel assay (FAGP, BioFire Diagnostics-bioMérieux, Italy), 200
103 μ l of each stool sample in Cary-Blair transport medium (Faecal swab; Copan, Italy) were used. The
104 FAGP is a multiplexed PCR, revealing 22 pathogens: *Campylobacter* (*C. jejuni*, *C. coli*, and *C.*
105 *upsaliensis*), *Clostridioides difficile* (toxin A/B), *Plesiomonas shigelloides*, *Salmonella*, *Yersinia*
106 *enterocolitica*, *Vibrio* (*V. parahaemolyticus*, *V. vulnificus*, and *V. cholerae*, with specific detection
107 of *V. cholerae*), enteroaggregative *Escherichia coli* (EAEC), enteropathogenic *Escherichia coli*
108 (EPEC), enterotoxigenic *Escherichia coli* (ETEC), Shiga-like toxin-producing *Escherichia coli*
109 (STEC, with specific detection of *E. coli* O157), *Shigella*/enteroinvasive *Escherichia coli* (EIEC),
110 *Cryptosporidium spp.*, *Cyclospora cayetanensis*, *Entamoeba histolytica*, *Giardia lamblia*,
111 adenovirus (AdV) F40/41, astrovirus, norovirus (NoV) genogroup GI/GII, rotavirus (RV) group A,
112 and sapovirus (SaV) genogroups I, II, IV, and V. The assay lasting nearly 1 hour was performed in
113 the FilmArray 2.0 platform.

114 In case of *Clostridioides difficile* detection by FAGP for a sample with a medical prescription
115 requiring this testing, a qualitative assay (Illumigen TM *C.difficile*, Meridian Bioscience, USA),
116 based on the Loop-mediated isothermal amplification (LAMP), was performed [9].
117 For viral diagnostic purpose, when an adequate aliquot of sample was available (2,023 cases,
118 97.9%), an Enterovirus-targeting real-time PCR (Enterovirus Q-PCR Alert kit, ElitechGroup, Italy)
119 was performed.

120

121 2.3 Conventional diagnostics methods

122 In case of bacteria detection by FAGP, the sample was submitted to conventional methods for
123 isolation and/or identification purposes (data not shown) [10]. In case of *Clostridioides difficile*
124 revealing by FAGP and LAMP, the detection of glutamate dehydrogenase enzyme (GDH) and
125 toxins A/B by immunocromatographic assay (IC, *C.difficile* Quick check complete, Techlab, USA)
126 as well as culture were performed [9].

127 For virus detection, electron microscopy was also performed (data not included) [10].

128 In case of parasites detection by FAGP, the sample was submitted to microscopic examination,
129 *Giardia intestinalis*/*Cryptosporidium* IC, immunofluorescence, and cultures (data not shown) [10-
130 13].

131

132 2.4 Statistical analysis

133 The chi-square test was performed by GraphPad Prism software. $P < 0.05$ was considered
134 statistically significant.

135 3. RESULTS

136 3.1 Prevalence of enteric pathogens in the study population

137 A total of 2,066 samples were analyzed, as described in the Methods section. AGE was most
138 common in pediatrics aged 0-5 years (65.3%) and in males than in females, with a ratio of 10:8
139 (Table 1). The rate of hospitalized children was 62.7%, showing in 2020 a decrease of -21.5% vs.
140 2019 and of -33.8% vs. 2018.

141 The FAGP identified at least one etiologic agent in 1,101 samples (53.3%). Figure 1 shows the
142 positivity rates of the pathogens detected; EPEC was the most frequent (21.14%), followed by
143 *Clostridioides difficile* (11.5%), NoV (11.44%), and *Campylobacter* (10.17%). *Cyclospora*
144 *cayetanensis*, *Vibrio cholerae* and *Entamoeba histolytica* were not detected.

145 A total of 1,495 pathogens was revealed. Of these, 949 (63.5%) were bacteria, 476 (31.8%) viruses,
146 and 70 (4.7%) parasites. Specifically, 615 pathogens (41.1%) were revealed in 2018, 551 (36.9%) in
147 2019, and 329 (22%) in 2020 (41.1% vs. 22%, $P<0.0001$, and 36.9% vs. 22%, $P<0.0001$).
148 Single infections were 796 (72.3%) and mixed infections 305 (27.7%) (72.3% vs. 27.7%;
149 $P<0.0001$).

150 Co-infections with two pathogens were detected in 227 (20.6%) of the 1,101 positive samples,
151 compared to 66 (6%) with three and 12 (1.1%) with more than three. The percentage difference in
152 the number of co-infections with two (20.6%) and more than three pathogens (1.1%) was significant
153 ($P<0.0001$). Overall, 147 different co-infections combinations were found (Table 2). The most
154 common included either bacteria (*Campylobacter*, 7.8%, and *Clostridioides difficile*, 6.2%) or NoV
155 (5.2%) in association with EPEC.

156 Of the 172 samples positive for *Clostridioides difficile* by FAGP, 13 samples (7.6%) belonging to
157 children >2 years old hospitalized in oncologic wards had a medical order requiring *Clostridioides*
158 *difficile* testing. Of these, 12 cases (92.3%) resulted positive by LAMP. Among these, GDH was
159 revealed in 11 cases (91.7%) and toxin A/B in 3 cases (25%). Finally, in 4 cases (33%)
160 *Clostridioides difficile* strains were isolated.

161 The RT-PCR assay for Enterovirus gave positive results in 156 (7.7%) of the examined samples; of
162 those, 63 (40.4%) were single infections.

163

164 3.2 Age distribution of enteric pathogens

165 Concerning the distribution of positive samples by age, 68.2% (751/1,101) were from children aged
166 0-5 years, 19.8% (218/1,101) from children aged 6-10 years, and 12% (135/1,101) from children
167 aged 11-14 years. Of the 1,495 pathogens revealed, 1,051 (70.4%) were detected in children aged 0-
168 5 years, 273 (18.2%) in children aged 6-10 years, and 171 (11.4%) in children aged 11-14 years
169 (70.4% vs. 11.4%, $P<0.0001$). Of the pathogens revealed in children aged 0-5 years, 58.5% were
170 bacteria, 38% viruses, and 3.5% parasites.

171 Concerning the distribution of co-infections by age, 226 (74.1%) were detected in children aged 0-5
172 years, 51 (16.7%) in children aged 6-10 years, and 28 (9.2%) in children aged 11-14 years (Table
173 3). Co-infections between EPEC and either *Clostridioides difficile* (17 cases) or *Campylobacter* and
174 NoV (16 cases each) prevailed in children aged 0-5 years (Table 3). Co-infections between EPEC
175 and NoV (5 cases) predominated in children aged 6-10 years, while those between EPEC and
176 *Campylobacter* (8 cases) in children aged 11-14 years.

177

178 3.3 Seasonality of enteric pathogens

179 The number of positive samples decreased from 53.9% (445/825) in 2018 and 56.1% (408/727) in
180 2019 to 48.2% (248/514) in 2020 (53.9% vs. 48.2%, $P=0.043$).

181 Supplementary table 1 shows the monthly distribution of all pathogens revealed, while Figure 2 that
182 of the most common pathogens.

183 EPEC (Fig. 2A) was systematically detected except in March 2019, predominating in summer and
184 early autumn. No seasonal trends were apparent for *Clostridioides difficile* (Fig. 2B), contrarily to
185 *Campylobacter* and EAEC, showing increased rates during summer (Fig. 2D and 2H). *Salmonella*
186 (Fig. 2G) increased its detection rate in summer of 2018 and 2020.

187 Seasonal prevalence was found for NoV in winter (Fig. 2C), while RV detection increased in spring
188 (Fig. 2E). AdV did not seem to vary hugely its percentage of positive cases during the study, but
189 two peaks passing the median more than twice were found in December 2018 (18%) and April 2019
190 (27%) (Fig. 2F).

191 Different trends were observed in 2020 during the SARS-CoV-2 lockdown (from March 9 to May
192 18) when compared to previous years. The circulation of AdV and EAEC (Fig. 2F and 2H) was
193 interrupted, while for EPEC, *Clostridioides difficile*, NoV, *Campylobacter*, and *Salmonella* (Fig.
194 2A, 2B, 2C, 2D, 2G) the detection rate decreased considerably under the median.

195 **4. DISCUSSION**

196 This study reveals the epidemiology of AGE pathogens in 2,066 children who underwent stool
197 testing by FAGP from 2018 to 2020.

198 Molecular methods have greatly increased the sensitivity of pathogen detection expanding their
199 involvement as AGE etiologic agents [14], although they do not yield an isolate and might detect
200 nucleic acids from non-viable microorganisms unrelated to illness. Multiplex PCR assays may
201 present limitation in finding the true etiologic agent in case of multiple pathogens detection and
202 need to perform culture isolation and antibiotics sensitivity evaluation in case of bacterial
203 identification [14].

204 FAGP has been usefully included in our diagnostic algorithm [10], with the goal of limiting the use
205 of conventional methods in light of its high sensitivity and reproducibility [15].

206 In the study population, 53.3% of the samples resulted positive in agreement with previous data
207 [10,15]. Of the positive samples, 68.2% were from children aged 0-5 years.

208 FAGP detected a higher frequency of single infections (72.3%) mostly caused by bacteria (59.2%),
209 also consistent with literature data [16]. The more prevalent pathogens were EPEC (21.14%),
210 *Clostridioides difficile* (11.5%), NoV (11.44%), and *Campylobacter* (10.17%).

211 *Clostridioides difficile* and *Campylobacter* showed higher rates than in our previous survey [10]. In
212 contrast, RV decreased its frequency, as a likely consequence of the vaccine administration [14,17].
213 Antithetical considerations apply to NoV, being the vaccine candidates under study.

214 Although EPEC and EAEC were frequently detected, their etiological role remains unclear [18,19].

215 Interestingly, AGE-related inflammation modulates the intestinal microbiota, favoring the unusual
216 growth of *Enterobacteriaceae* [20].

217 *Clostridioides difficile* was the second most common pathogen. This finding is difficult to interpret,
218 given the high rate of asymptomatic carriage in young infants (<12 months) and frequent co-
219 detection of other pathogens [21,22]. Therefore, testing should be performed when specifically
220 requested and consultation with the pediatrician is recommended [22]. In the study population, only

221 13 samples had appropriate clinical information (data not shown). Being *Clostridioides difficile*
222 more frequently detected in single infections, antibiotic treatments may have favored its
223 proliferation, also considering the low rate (25%) of toxigenic samples.

224 Campylobacteriosis shows high incidence in the study population, contrarily to previous results
225 [23]. In this regard, Italian data are likely to be underestimated, being not a statutory notification
226 illness. Other Authors showed that *Campylobacteriosis* is increasing [24].

227 Important, FAGP allowed detecting *Plesiomonas shigelloides*, which is frequently unnoticed by
228 conventional methods [25].

229 A frequent co-detection of viruses and bacteria was assessed especially in young children,
230 according to Park et al. [26]. Although co-infecting viral and bacterial pathogens cause more severe
231 gastroenteritis with higher probability of hospitalization [27], the knowledge on their etiological
232 role remains incomplete [28]. Overall, *Escherichia coli* was the most prevalent pathogen in co-
233 infections, according to Vergadi et al. [28].

234 EPEC, *Campylobacter* and EAEC predominated in summer, NoV in winter, and RV in spring.
235 These seasonality differences confirm the need of continuous surveillance. These findings were in
236 agreement with previous studies [10,29,30], but conflicting results were reported [31,32].

237 During the lockdown imposed because of the SARS-CoV-2 pandemic, care for children in Italy
238 have been kept to minimal standards. Although gastrointestinal manifestations are observed during
239 SARS-CoV-2 infection [33], in 2020 diminished both hospitalizations (342 in 2020 vs. 517 in
240 2018) and pathogens detection rates (22% in 2020 vs. 41.1% in 2018, $P<0.0001$). Individual
241 protection measures and social distancing interrupted the circulation of AdV and EAEC, and
242 decreased that of EPEC, *Clostridioides difficile*, NoV, *Campylobacter*, and *Salmonella*.

243 Accordingly, lower rates of infectious disease transmission and delay in attendances to pediatric
244 departments, with the tendency to seek hospital care only in case of severe or unremitting symptoms
245 were described [34].

246 The reported findings focused on severe AGE cases, causing a high percentage of hospitalizations.

247 The rapid diagnosis by FAGP helped the pediatricians in the management of patients, allowing a

248 faster decision on the need for hospitalization. Since self-limited and asymptomatic cases were not

249 examined, cautious epidemiological conclusions should be drawn.

250

251 **Conclusions**

252 Timely diagnosis improves the surveillance of the burden associated to AGE in children. Despite

253 the costs of FAGP, the reduction in workload, antibiotic use and hospitalization renders this assay

254 cost-effective. Our findings help to estimate the epidemiology of diarrhoea causative agents in

255 children. Moreover, we tracked pathogen seasonality, reinforcing the need for accurate surveillance

256 to control AGE.

257 **REFERENCES**

- 258 1. World Health Organization. Diarrhoeal disease 2017. [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease)
- 259 [sheets/detail/diarrhoeal-disease](https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease)
- 260 2. Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. The New England
- 261 Journal of Medicine 2004;350:38–47. <https://doi.org/10.1056/NEJMcp031534>.
- 262 3. Das JK, Salam RA, Bhutta ZA. Global burden of childhood diarrhea and interventions.
- 263 Current Opinion in Infectious Diseases 2014;27.
- 264 <https://doi.org/10.1097/QCO.000000000000096>.
- 265 4. Medici MC, Martinelli M, Abelli LA, Ruggeri FM, di Bartolo I, Arcangeletti MC, et al.
- 266 Molecular epidemiology of norovirus infections in sporadic cases of viral gastroenteritis
- 267 among children in Northern Italy. Journal of Medical Virology 2006;78.
- 268 <https://doi.org/10.1002/jmv.20723>.
- 269 5. Medici MC, Martinelli M, Arcangeletti MC, Pinardi F, De Conto F, Dodi I, et al.
- 270 Epidemiological aspects of human rotavirus infection in children hospitalized with acute
- 271 gastroenteritis in an area of northern Italy. Acta Biomedica de l'Ateneo Parmense 2004;75.
- 272 6. Mattei A, Sbarbati M, Fiasca F, Angelone AM, Mazzei MC, di Orio F. Temporal trends in
- 273 hospitalization for rotavirus gastroenteritis: A nationwide study in Italy, 2005–2012. Human
- 274 Vaccines and Immunotherapeutics 2016;12.
- 275 <https://doi.org/10.1080/21645515.2015.1081726>.
- 276 7. Elliott EJ. Acute gastroenteritis in children. British Medical Journal 2007;334.
- 277 <https://doi.org/10.1136/bmj.39036.406169.80>.
- 278 8. Freeman K, Mistry H, Tsertsvadze A, Royle P, McCarthy N, Taylor-Phillips S, et al.
- 279 Multiplex tests to identify gastrointestinal bacteria, viruses and parasites in people with
- 280 suspected infectious gastroenteritis: A systematic review and economic analysis. Health
- 281 Technology Assessment 2017;21. <https://doi.org/10.3310/hta21230>.

- 282 9. Calderaro A, Buttrini M, Martinelli M, Farina B, Moro T, Montecchini S, et al. Rapid
283 classification of *Clostridioides difficile* strains using maldi-tof ms peak-based assay in
284 comparison with PCR-ribotyping. *Microorganisms* 2021;9.
285 <https://doi.org/10.3390/microorganisms9030661>.
- 286 10. Calderaro A, Martinelli M, Buttrini M, Montecchini S, Covan S, Rossi S, et al. Contribution
287 of the FilmArray® Gastrointestinal Panel in the laboratory diagnosis of gastroenteritis in a
288 cohort of children: a two-year prospective study. *International Journal of Medical*
289 *Microbiology* 2018;308. <https://doi.org/10.1016/j.ijmm.2018.04.007>.
- 290 11. Calderaro A, Gorrini C, Montecchini S, Peruzzi S, Piccolo G, Rossi S, et al. Evaluation of a
291 real-time polymerase chain reaction assay for the laboratory diagnosis of giardiasis.
292 *Diagnostic Microbiology and Infectious Disease* 2010;66.
293 <https://doi.org/10.1016/j.diagmicrobio.2009.10.004>.
- 294 12. Calderaro A, Montecchini S, Gorrini C, Dettori G, Chezzi C. Similar diagnostic
295 performances of antigen detection and nucleic acid detection of *Cryptosporidium* spp. in a
296 low-prevalence setting. *Diagnostic Microbiology and Infectious Disease* 2011;70.
297 <https://doi.org/10.1016/j.diagmicrobio.2010.11.017>.
- 298 13. Calderaro A, Montecchini S, Rossi S, Gorrini C, De Conto F, Medici MC, et al. Intestinal
299 parasitoses in a tertiary-care hospital located in a non-endemic setting during 2006-2010.
300 *BMC Infectious Diseases* 2014;14. <https://doi.org/10.1186/1471-2334-14-264>.
- 301 14. Guarino A, Aguilar J, Berkley J, Broekaert I, Vazquez-Frias R, Holtz L, et al. Acute
302 Gastroenteritis in Children of the World: What Needs to Be Done? *Journal of Pediatric*
303 *Gastroenterology and Nutrition* 2020;70. <https://doi.org/10.1097/MPG.0000000000002669>.
- 304 15. Piralla A, Lunghi G, Ardissino G, Girello A, Premoli M, Bava E, et al. FilmArray™ GI
305 panel performance for the diagnosis of acute gastroenteritis or hemorrhagic diarrhea. *BMC*
306 *Microbiology* 2017;17. <https://doi.org/10.1186/s12866-017-1018-2>.

- 307 16. O’Neal M, Murray H, Dash S, Al-Hasan MN, Justo JA, Bookstaver PB. Evaluating
308 appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain
309 reaction gastrointestinal testing within a hospital system. *Therapeutic Advances in*
310 *Infectious Disease* 2020;7. <https://doi.org/10.1177/2049936120959561>.
- 311 17. Sabbatucci M, Odone A, Signorelli C, Siddu A, Maraglino F, Rezza G. Improved Temporal
312 Trends of Vaccination Coverage Rates in Childhood after the Mandatory Vaccination Act,
313 Italy 2014–2019. *Journal of Clinical Medicine* 2021;10.
314 <https://doi.org/10.3390/jcm10122540>.
- 315 18. Beczkiewicz A, Cebelinski E, Decuir M, Lappi V, Wang X, Smith K, et al. High Relative
316 Frequency of Enteraggregative *Escherichia coli* among Patients with Reportable Enteric
317 Pathogens, Minnesota, 2016-2017. *Clinical Infectious Diseases* 2019;69.
318 <https://doi.org/10.1093/cid/ciy890>.
- 319 19. Hu J, Torres AG. Enteropathogenic *Escherichia coli*: Foe or innocent bystander? *Clinical*
320 *Microbiology and Infection* 2015;21. <https://doi.org/10.1016/j.cmi.2015.01.015>.
- 321 20. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-
322 Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of
323 Enterobacteriaceae. *Cell Host and Microbe* 2007;2.
324 <https://doi.org/10.1016/j.chom.2007.06.010>.
- 325 21. Furuya-Kanamori L, Marquess J, Yakob L, Riley T v., Paterson DL, Foster NF, et al.
326 Asymptomatic *Clostridium difficile* colonization: Epidemiology and clinical implications.
327 *BMC Infectious Diseases* 2015;15. <https://doi.org/10.1186/s12879-015-1258-4>.
- 328 22. Sammons JS, Toltzis P. Pitfalls in Diagnosis of Pediatric *Clostridium difficile* Infection.
329 *Infectious Disease Clinics of North America* 2015;29.
330 <https://doi.org/10.1016/j.idc.2015.05.010>.

- 331 23. Lucarelli C, Dionisi AM, Trezzi L, Farina C, Passera M, Kärki T, et al. Molecular and
332 epidemiological analysis of a campylobacter jejuni outbreak in Northern Italy in November
333 2013. Foodborne Pathogens and Disease 2016;13. <https://doi.org/10.1089/fpd.2015.2104>.
- 334 24. Platts-Mills JA, Kosek M. Update on the burden of Campylobacter in developing countries.
335 Current Opinion in Infectious Diseases 2014;27.
336 <https://doi.org/10.1097/QCO.0000000000000091>.
- 337 25. Michael Janda J, Abbott SL, McIver CJ. Plesiomonas shigelloides revisited. Clinical
338 Microbiology Reviews 2016;29. <https://doi.org/10.1128/CMR.00103-15>.
- 339 26. Park S, Hitchcock MM, Gomez CA, Banaei N. Is follow-up testing with the filmarray
340 gastrointestinal multiplex PCR panel necessary? Journal of Clinical Microbiology 2017;55.
341 <https://doi.org/10.1128/JCM.02354-16>.
- 342 27. Valentini D, Vittucci AC, Grandin A, Tozzi AE, Russo C, Onori M, et al. Coinfection in
343 acute gastroenteritis predicts a more severe clinical course in children. European Journal of
344 Clinical Microbiology and Infectious Diseases 2013;32. [https://doi.org/10.1007/s10096-013-
345 1825-9](https://doi.org/10.1007/s10096-013-1825-9).
- 346 28. Vergadi E, Maraki S, Dardamani E, Ladomenou F, Galanakis E. Polymicrobial
347 gastroenteritis in children. Acta Paediatrica, International Journal of Paediatrics 2021;110.
348 <https://doi.org/10.1111/apa.15854>.
- 349 29. Festini F, Cocchi P, Mambretti D, Tagliabue B, Carotti M, Ciofi D, et al. Nosocomial
350 Rotavirus Gastroenteritis in pediatric patients: A multi-center prospective cohort study.
351 BMC Infectious Diseases 2010;10. <https://doi.org/10.1186/1471-2334-10-235>.
- 352 30. Medici MC, Tummolo F, Martella V, De Conto F, Arcangeletti MC, Pinardi F, et al.
353 Emergence of novel recombinant GII.P16_GII.2 and GII.P16_GII.4 Sydney 2012 norovirus
354 strains in Italy, winter 2016/2017. New Microbiologica 2018;25.
355 <https://doi.org/10.1007/s12560-017-9278-4>.

- 356 31. Amisano G, Fornasero S, Migliaretti G, Caramello S, Tarasco V, Savino F. Diarrheogenic
357 *Escherichia coli* in acute gastroenteritis in infants in north-west Italy. *New Microbiologica*
358 2011;34.
- 359 32. Iannetti S, Calistri P, Di Serafino G, Marotta F, Alessiani A, Antoci S, et al. *Campylobacter*
360 *jejuni* and *Campylobacter coli*: prevalence, contamination levels, genetic diversity and
361 antibiotic resistance in Italy. *Veterinaria Italiana* 2020;56.
362 <https://doi.org/10.12834/VetIt.1819.9596>.
- 363 33. Matthai J, Shanmugam N, Sobhan P. Coronavirus Disease (COVID-19) and the
364 Gastrointestinal System in Children. *Indian Pediatrics* 2020;57.
365 <https://doi.org/10.1007/s13312-020-1851-5>.
- 366 34. Rusconi F, Di Fabrizio V, Puglia M, Sica M, De Santis R, Masi S, et al. Delayed
367 presentation of children to the emergency department during the first wave of COVID-19
368 pandemic in Italy: Area-based cohort study. *Acta Paediatrica* 2021;110.
369 <https://doi.org/10.1111/apa.16019>.

370

371

372

373

374

375

376 **FIGURES AND TABLES LEGENDS**

377

378 **Figure 1.** Distribution of enteric pathogens revealed by FAGP in stool samples from 2,066 children.

379 The number of pathogens detected per year is shown below the histograms. The prevalence of each
380 pathogen (%) was evaluated in reference to the total number of pathogens detected in the study
381 period.

382

383 **Figure 2.** Monthly distribution of the most frequently detected pathogens in stool samples from

384 2,066 children. A: EPEC; B: *Clostridioides difficile*; C: Norovirus; D: *Campylobacter*; E:

385 Rotavirus; F: Adenovirus; G: *Salmonella*; H: EAEC.

386

387 **Table 1.** Demographic data of the 2,066 children with AGE whose stool samples were analyzed

388 with FAGP from 2018 to 2020.

389

390 **Table 2.** Different combinations of 305 co-infections detected in 1,101 positive stool samples.

391

392 **Table 3.** Most frequent co-infections detected in 2,066 children divided by age.

393 **Author's contributions**

394 Flora De Conto: Conceptualization, Methodology, Data acquisition, Writing, Editing, Validation,
395 and Resource; Sharon Di Stefano: Investigation, Data curation and Visualization; Mirko Buttrini:
396 Data curation, Methodology, and Visualization; Clara Maccari: Data curation; Maria Cristina
397 Arcangeletti: Data acquisition and curation; Adriana Calderaro: Data acquisition, Reviewing, and
398 Validation; Carlo Chezzi: Reviewing and Validation.

399

400 **Ethical approval**

401 This article does not describe any studies with human participants or animals.

402 The samples were sent to the University-Hospital of Parma for diagnostic purposes. Ethical
403 approval at the University-Hospital of Parma is required when samples are used for applications
404 other than laboratory diagnosis.




Figure 1




Figure 2

Table 1

| Features | Number (%) |
|---------------------------|-------------------|
| Males | 1174 (56.8) |
| Females | 892 (43.2) |
| Mean age (years) \pm SD | 4.4 \pm 4.2 |
| Median age (years) | 2.9 |
| 0-5 years | 1350 (65.3) |
| 6-10 years | 431 (20.9) |
| 11-14 years | 285 (13.8) |
| Inpatients | 1295 (62.7) |
| Outpatients | 771 (37.3) |

SD - standard deviation

Table 2

| Two pathogens | N° |
|---|------------|
| <i>Campylobacter</i> + EPEC | 24 |
| <i>Clostridioides difficile</i> + EPEC | 19 |
| EPEC + NoV | 16 |
| EAEC + EPEC | 11 |
| <i>Salmonella</i> + STEC | 11 |
| AdV + EPEC | 10 |
| <i>Cryptosporidium</i> + EPEC | 8 |
| <i>Clostridioides difficile</i> + RV | 8 |
| AdV + NoV | 7 |
| AdV + RV | 7 |
| <i>Campylobacter</i> + <i>Clostridioides difficile</i> | 7 |
| <i>Clostridioides difficile</i> + NoV | 6 |
| <i>Clostridioides difficile</i> + SaV | 6 |
| EAEC + NoV | 5 |
| NoV + RV | 5 |
| EPEC + SaV | 5 |
| EPEC + <i>Yersinia enterocolitica</i> | 5 |
| <i>Campylobacter</i> + STEC | 4 |
| Less frequent infections with two pathogens | 63 |
| Total | 81 |
| Three pathogens | |
| <i>Campylobacter</i> + <i>Clostridioides difficile</i> + EPEC | 4 |
| AdV + <i>Clostridioides difficile</i> + EPEC | 3 |
| EAEC + ETEC + STEC | 3 |
| AdV + <i>Campylobacter</i> + EPEC | 2 |
| <i>Campylobacter</i> + EPEC + RV | 2 |
| <i>Clostridioides difficile</i> + EPEC + NoV | 2 |
| <i>Cryptosporidium</i> + ETEC + EPEC | 2 |
| EPEC + NoV + RV | 2 |
| Less frequent infections with three pathogens | 46 |
| Total | 54 |
| More than three pathogens | |
| AdV + EAEC + EPEC + RV | 1 |
| AdV + EPEC + ETEC + SaV | 1 |
| <i>Campylobacter</i> + EAEC + EIEC + <i>Salmonella</i> | 1 |
| <i>Campylobacter</i> + EAEC + EPEC + NoV | 1 |
| <i>Campylobacter</i> + EAEC + EPEC + RV | 1 |
| <i>Clostridioides difficile</i> + EAEC + EPEC + RV | 1 |
| <i>Cryptosporidium</i> + EAEC + EIEC + <i>Salmonella</i> | 1 |
| <i>Cryptosporidium</i> + EAEC + EPEC + SaV | 1 |
| EAEC + EPEC + ETEC + NoV | 1 |
| EAEC + EPEC + ETEC + NoV + SaV | 1 |
| EAEC + EPEC + NoV + RV | 1 |
| EAEC + STEC + EIEC + <i>Salmonella</i> | 1 |
| Total | 12 |
| Total | 147 |

Table 3

| Co-infections | N° | Age group (years) |
|--|------------|------------------------------|
| EPEC | | |
| <i>Clostridioides difficile</i> | 17 | |
| <i>Campylobacter</i> | 16 | |
| NoV | 16 | |
| AdV | 10 | |
| EAEC | 8 | |
| <i>Clostridioides difficile</i> | | |
| RV | 8 | |
| AdV | 7 | 0-5 |
| NoV | 6 | |
| <i>Campylobacter</i> | 6 | |
| <i>Campylobacter</i> + EPEC | 4 | |
| NoV | | |
| AdV | 6 | |
| <i>Clostridioides difficile</i> | 6 | |
| EPEC | | |
| NoV | 5 | |
| EAEC | 3 | 6-10 |
| <i>Cryptosporidium</i> | 2 | |
| <i>Clostridioides difficile</i> | 2 | |
| EPEC | | |
| <i>Campylobacter</i> | 8 | 11-14 |
| Total | 130 | |

Supplementary table 1. Monthly distribution of pathogens detected by the FAGP in 2,066 children with AGE.

| 2018 | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % |
|---------------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------|-------------|
| EPEC | 8 | 4 | 4 | 6 | 12 | 15 | 17 | 22 | 16 | 9 | 14 | 13 | 140 | 23 |
| Norovirus | 8 | 9 | 11 | 4 | 4 | 8 | | 2 | 3 | 7 | 4 | 10 | 70 | 11.3 |
| <i>Clostridioides difficile</i> | 7 | 5 | 6 | 9 | 4 | 5 | 9 | 3 | 4 | 2 | 7 | 6 | 67 | 11 |
| <i>Campylobacter</i> | 4 | 2 | 4 | 6 | 2 | 2 | 9 | 5 | 3 | 6 | 4 | 2 | 49 | 8 |
| Rotavirus | 6 | 3 | 5 | 10 | 4 | | 6 | 6 | 1 | 2 | 2 | 4 | 49 | 8 |
| Adenovirus | 1 | 4 | 2 | 2 | 6 | 4 | 2 | 2 | | 3 | 2 | 12 | 40 | 6.5 |
| EAEC | | 1 | 3 | 5 | 5 | 2 | 4 | 6 | 5 | 4 | 1 | 3 | 39 | 6.3 |
| <i>Salmonella</i> | | 2 | 2 | 3 | 3 | 1 | 2 | 3 | 6 | 5 | 3 | 3 | 33 | 5.3 |
| Sapovirus | 7 | 3 | 3 | 3 | 2 | | | | 2 | 3 | 1 | 7 | 31 | 5 |
| <i>Cryptosporidium</i> | | | | | 1 | 2 | 5 | 8 | 3 | 3 | 3 | 1 | 26 | 4.2 |
| STEC | 3 | 1 | 1 | 1 | | 2 | 2 | | 4 | 6 | | | 20 | 3.2 |
| <i>Yersinia enterocolitica</i> | 1 | | | 2 | 3 | | 2 | 3 | 1 | 1 | 1 | | 14 | 2.2 |
| Astrovirus | 3 | 2 | 1 | 1 | 3 | | | | | | | 2 | 12 | 2 |
| ETEC | | | 1 | | | | 1 | 3 | 3 | | | 3 | 11 | 1.8 |
| <i>Giardia intestinalis</i> | | 1 | | | | | 1 | 1 | 2 | 1 | | 1 | 7 | 1.1 |
| <i>E. coli</i> O157 | | 1 | | | | | 1 | 2 | 1 | | | | 5 | 0.8 |
| EIEC | | | | | | | | 1 | | | 1 | | 2 | 0.3 |
| Total | | | | | | | | | | | | | 615 | |

| 2019 | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % |
|---------------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------|-------------|
| EPEC | 4 | 5 | | 4 | 9 | 4 | 14 | 15 | 14 | 15 | 9 | 5 | 98 | 18 |
| Norovirus | 5 | 17 | 6 | 7 | 1 | 6 | | 2 | | 5 | 5 | 12 | 66 | 12 |
| <i>Clostridioides difficile</i> | 3 | 8 | 7 | 7 | 8 | 4 | 5 | 8 | 4 | 3 | 5 | 3 | 65 | 11.8 |
| Adenovirus | 2 | 3 | | 16 | 7 | 6 | 3 | | 3 | 9 | 3 | 1 | 53 | 9.6 |
| Rotavirus | 6 | 2 | 3 | 11 | 11 | | 2 | 3 | 2 | 4 | 4 | 2 | 50 | 9 |
| <i>Campylobacter</i> | | | 3 | 5 | 8 | 4 | 8 | 10 | 3 | 4 | 2 | 2 | 49 | 8.8 |
| <i>Salmonella</i> | 4 | 4 | 1 | | 5 | 2 | 2 | 4 | 1 | 5 | 1 | 2 | 31 | 5.6 |
| EAEC | 1 | 2 | 1 | 4 | | 2 | 3 | 5 | 3 | 3 | 2 | 2 | 28 | 5 |
| STEC | | 2 | | | | 1 | 3 | 4 | 6 | 3 | 3 | | 22 | 4 |
| Sapovirus | 4 | 8 | 1 | 1 | 2 | | | | 1 | | | 2 | 19 | 3.4 |
| <i>Cryptosporidium</i> | | | | | 1 | 1 | 2 | 4 | 3 | 3 | 1 | 1 | 16 | 3 |
| Astrovirus | 1 | 3 | | 3 | 2 | 1 | | | | | 1 | 2 | 13 | 2.3 |
| EIEC | 1 | 3 | | 2 | | | | 1 | 2 | 1 | | 1 | 11 | 2 |
| ETEC | 1 | | 1 | | | 1 | | 3 | 2 | 1 | 2 | | 11 | 2 |
| <i>Giardia intestinalis</i> | | 2 | 3 | | | | 1 | 1 | | | 2 | | 9 | 1.6 |
| <i>Yersinia enterocolitica</i> | | 1 | | | 1 | 1 | 1 | | 1 | | | | 5 | 1 |
| <i>E. coli</i> O157 | | | | | | | | | 2 | | | | 2 | 0.4 |
| <i>P. shigelloides</i> | 1 | | 1 | | | | | | | | | | 2 | 0.4 |
| <i>Vibrio</i> | | | | | | | | | 1 | | | | 1 | 0.1 |
| Total | | | | | | | | | | | | | 551 | |

| 2020 | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % |
|---------------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------|-------------|
| EPEC | 5 | 9 | 1 | 1 | 5 | 2 | 5 | 11 | 14 | 7 | 8 | 10 | 78 | 23.7 |
| <i>Campylobacter</i> | 2 | 2 | 2 | 2 | 7 | 8 | 7 | 5 | 5 | 5 | 4 | 5 | 54 | 16.4 |
| <i>Clostridioides difficile</i> | 2 | 8 | 3 | 3 | 3 | 2 | 5 | 1 | 2 | 3 | 7 | 1 | 40 | 12.1 |
| Norovirus | 17 | 15 | 1 | | | | | | | | 2 | | 35 | 10.6 |
| <i>Salmonella</i> | | 2 | 1 | 1 | 3 | 2 | 8 | 5 | 1 | 2 | 1 | 4 | 30 | 9.1 |
| Rotavirus | 3 | 2 | | 3 | 2 | 2 | 2 | 5 | | 3 | | 2 | 24 | 7.2 |
| EAEC | 3 | 3 | | | | 1 | 4 | | 1 | 1 | 2 | 1 | 16 | 5 |
| STEC | | 1 | | | 1 | 1 | 4 | | 2 | 3 | | 2 | 14 | 4.2 |
| <i>Cryptosporidium</i> | | | | | | 1 | 3 | 1 | 3 | 3 | | | 11 | 3.3 |
| Adenovirus | 3 | 2 | | | | | 1 | | 1 | | 1 | | 8 | 2.4 |
| <i>Yersinia enterocolitica</i> | 1 | | 1 | 2 | | | 1 | | | | | 1 | 6 | 2 |
| ETEC | 2 | 1 | | | | | | | 1 | 1 | | | 5 | 1.5 |
| Astrovirus | 2 | 1 | 1 | | | | | | | | | | 4 | 1.2 |
| Sapovirus | 1 | 2 | | | | | | | | | | | 3 | 1 |
| <i>Giardia intestinalis</i> | | | | | | | | 1 | | | | | 1 | 0.3 |
| Total | | | | | | | | | | | | | 329 | |